Division of Rheumatology Research Studies

The purpose of this registry is to study the long-term effects and safety of Abatacept(Orencia) as used for the treatment of Juvenile Idiopathic Arthritis(JIA). JIA patients that are currently taking Abatacept may be eligible to participate in this study.

The purpose of this study is to find out if the study drug, Anifrolumab, is effective and safe for pediatric participants with moderate to severe active systemic lupus erythematosus (SLE) while on background standard of care therapy.

The purpose of this study is to find out how well surveys can measure disease activity in kids with lower back arthritis.

The purpose of this research study is to learn more about the normal function of blood vessels in healthy children and adolescents.

This study hopes to revise the currently used criteria for diagnoses of Juvenile Idiopathic Arthritis (JIA).

The purpose of this study is to find out if the study drug, MAS825, is effective in preventing flares and safe for children with NLRC4-Gain of Function (GOF).

We are trying to learn more about the ways in which adolescents (12-17 years) are involved in decision making related to their chronic condition.

The Division of Rheumatology at CHOP is looking to engage healthy participants for several research studies with the goal of learning more about ways to improve the health and well-being of children and young adults.

The purpose of this study is to find out if the study drug, Obinutuzumab, is effective in achieving a complete renal response for adolescents with active class III or IV lupus nephritis.

This is a clinical trial to study the use of Tadekinig alfa or placebo (medication) in the treatment of NLRC4 MAS mutation or XIAP deficiency.

The purpose of this study is to see if a new investigational drug (Upadacitinib) is safe and well tolerated and also to determine the appropriate dose for subjects with polyarticular course juvenile arthritis (pcJIA).

This is a study to measure the effectiveness of the medication Voclosporin compared to placebo in adolescent patients with active lupus nephritis